paroxetine has been researched along with carvedilol in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bleske, BE; Brook, R; Kerber, K; Nielsen, J; Shea, M; Stout, SM; Welage, LS | 1 |
| Guo, P; Han, Y; Lai, J; Tai, Y; Tao, J; Wang, M; Wang, Q; Wang, Z; Zhou, W | 1 |
| Choudhary, MI; Jabeen, A; Rahman, N; Sheikh, S; Zafar, H | 1 |
1 review(s) available for paroxetine and carvedilol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for paroxetine and carvedilol
| Article | Year |
|---|---|
The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics.
Topics: Adult; Antihypertensive Agents; Area Under Curve; Blood Pressure; Carbazoles; Carvedilol; Cross-Over Studies; Drug Interactions; Female; Heart Rate; Humans; Male; Middle Aged; Paroxetine; Propanolamines; Selective Serotonin Reuptake Inhibitors; Stereoisomerism | 2010 |
8 other study(ies) available for paroxetine and carvedilol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Sustaining Circulating Regulatory T Cell Subset Contributes to the Therapeutic Effect of Paroxetine on Mice With Diabetic Cardiomyopathy.
Topics: Animals; Carvedilol; Cell Differentiation; Cells, Cultured; Diabetic Cardiomyopathies; Diet, High-Fat; Disease Models, Animal; G-Protein-Coupled Receptor Kinase 2; Immunity; Insulin; Male; Mice; Mice, Inbred C57BL; Paroxetine; Phosphatidylinositol 3-Kinases; Protective Agents; Proto-Oncogene Proteins c-akt; Signal Transduction; T-Lymphocytes, Regulatory; Th17 Cells; Treatment Outcome | 2020 |
Drug repurposing for the identification of new Bcl-2 inhibitors: In vitro, STD-NMR, molecular docking, and dynamic simulation studies.
Topics: Antineoplastic Agents; Carvedilol; Cell Line, Tumor; Citrates; Clomiphene; Clomipramine; Drug Repositioning; Drug Screening Assays, Antitumor; Humans; Magnetic Resonance Spectroscopy; Molecular Docking Simulation; Molecular Dynamics Simulation; Paroxetine; Proto-Oncogene Proteins c-bcl-2 | 2023 |